TY - JOUR
T1 - Marine pharmacology in 2018
T2 - Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action
AU - Mayer, Alejandro M.S.
AU - Pierce, Marsha L.
AU - Howe, Katelyn
AU - Rodríguez, Abimael D.
AU - Taglialatela-Scafati, Orazio
AU - Nakamura, Fumiaki
AU - Fusetani, Nobuhiro
N1 - Funding Information:
We thank the contributions of Linda Huang, Pharm. D. and Neal Patel from the Chicago College of Pharmacy, Midwestern University for literature retrieval, and Colleen Bannon, Midwestern University Library for Endnote database assistance. We also thank the secretarial assistance of Victoria Sears and Laura Phelps from the Pharmacology Department, College of Graduate Studies. We gratefully acknowledge financial support from Midwestern University to AMSM and KH; and NIH-SC1 Award (Grant 1SC1GM086271-01A1 ) of the University of Puerto Rico to ADR, and a grant from Regione Campania-POR Campania FESR 2014/2020 “Combattere la resistenza tumorale: piattaforma integrata multidisciplinare per un approccio tecnologico innovativo alle oncoterapie-Campania Oncoterapie” (Project N. B61G18000470007 ) to OTS. The content of this review is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
We thank the contributions of Linda Huang, Pharm. D. and Neal Patel from the Chicago College of Pharmacy, Midwestern University for literature retrieval, and Colleen Bannon, Midwestern University Library for Endnote database assistance. We also thank the secretarial assistance of Victoria Sears and Laura Phelps from the Pharmacology Department, College of Graduate Studies. We gratefully acknowledge financial support from Midwestern University to AMSM and KH; and NIH-SC1 Award (Grant 1SC1GM086271-01A1) of the University of Puerto Rico to ADR, and a grant from Regione Campania-POR Campania FESR 2014/2020 “Combattere la resistenza tumorale: piattaforma integrata multidisciplinare per un approccio tecnologico innovativo alle oncoterapie-Campania Oncoterapie” (Project N. B61G18000470007) to OTS. The content of this review is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© 2022 The Authors
PY - 2022/9
Y1 - 2022/9
N2 - The 2018 marine pharmacology literature review represents a continuation of the previous 11 reviews of a series initiated in 1998. Preclinical marine pharmacology research during 2018 was performed by investigators in 44 countries and contributed novel pharmacology for 195 marine compounds. The peer-reviewed marine natural products pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 53 compounds, 73 compounds which presented antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 69 compounds were reported to show miscellaneous mechanisms of action which may contribute upon further investigation to several pharmacological classes. Thus, in 2018, the preclinical marine natural product pharmacology pipeline continued to report novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, which currently contributes to therapeutic strategies for several disease categories.
AB - The 2018 marine pharmacology literature review represents a continuation of the previous 11 reviews of a series initiated in 1998. Preclinical marine pharmacology research during 2018 was performed by investigators in 44 countries and contributed novel pharmacology for 195 marine compounds. The peer-reviewed marine natural products pharmacology literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 53 compounds, 73 compounds which presented antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 69 compounds were reported to show miscellaneous mechanisms of action which may contribute upon further investigation to several pharmacological classes. Thus, in 2018, the preclinical marine natural product pharmacology pipeline continued to report novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, which currently contributes to therapeutic strategies for several disease categories.
KW - Drug
KW - Marine
KW - Pharmaceutical
KW - Pharmacology
KW - Pipeline
KW - Preclinical
KW - Review
KW - Sea
KW - Toxicology
UR - http://www.scopus.com/inward/record.url?scp=85136258313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136258313&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2022.106391
DO - 10.1016/j.phrs.2022.106391
M3 - Review article
C2 - 35944805
AN - SCOPUS:85136258313
VL - 183
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
M1 - 106391
ER -